Literature DB >> 19475534

Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.

E Radaelli1, R Ceruti, V Patton, M Russo, A Degrassi, V Croci, F Caprera, G Stortini, E Scanziani, E Pesenti, R Alzani.   

Abstract

Tumorigenesis in human glioblastoma multiforme (GBM) is driven by several genetic abnormalities with disruption of important molecular pathways, such as p53/MDM2/p14ARF and EGFR/PTEN/Akt/mTOR. The malignant progression of human GBM is also primarily associated with a peculiar multistep pathophysiological process characterized by intratumoral ischemic necrosis (i.e. pseudopalisading necrosis) and activation of the hypoxia-inducible factor (HIF)-1alpha pathway with consequent peritumoral microvascular proliferation and infiltrative behaviour. Predictable preclinical animal models of GBM should recapitulate the main pathobiological hallmarks of the human disease. In this study we describe two murine orthotopic xenograft models using U87MG and U251 human cell lines. Ten Balb/c nude male mice were orthotopically implanted with either U87MG (5 mice) or U251 (5 mice) cell lines. Intracranial tumor growth was monitored through Magnetic Resonance Imaging (MRI). Immunohistopathological examination of the whole cranium was performed 30 days after implantation. U251 orthotopic xenografts recapitulated the salient pathobiological features described for human GBM, including invasive behaviour, wide areas of pseudopalisading necrosis, florid peripheral angiogenesis, GFAP and vimentin expression, nonfunctional p53 expression, striking active-caspase-3 and HIF-1alpha expression along pseudopalisades. U87MG orthotopic xenografts proved to be very dissimilar from human GBM, showing expansile growth, occasional necrotic foci without pseudopalisades, intratumoral lacunar pattern of angiogenesis, lack of GFAP expression, functional p53 expression and inconsistent HIF-1alpha expression. Expression of pAkt was upregulated in both models. The results obtained suggest that the U251 orthotopic model may be proposed as a predictive and reliable tool in preclinical studies since it recapitulates the most salient pathobiological features reported for human GBM.

Entities:  

Mesh:

Year:  2009        PMID: 19475534     DOI: 10.14670/HH-24.879

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  46 in total

1.  Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Authors:  Nichole L Bryant; G Yancey Gillespie; Richard D Lopez; James M Markert; Gretchen A Cloud; Catherine P Langford; Hilal Arnouk; Yun Su; Hilary L Haines; Catalina Suarez-Cuervo; Lawrence S Lamb
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

2.  Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection.

Authors:  John Nemunaitis; Neil Senzer
Journal:  Mol Ther       Date:  2015-07       Impact factor: 11.454

3.  Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme.

Authors:  Lova Sun; Daniel Y Joh; Ajlan Al-Zaki; Melissa Stangl; Surya Murty; James J Davis; Brian C Baumann; Michelle Alonso-Basanta; Gary D Kaol; Andrew Tsourkas; Jay F Dorsey
Journal:  J Biomed Nanotechnol       Date:  2016-02       Impact factor: 4.099

4.  Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme.

Authors:  Brian C Baumann; Jay F Dorsey; Joseph L Benci; Daniel Y Joh; Gary D Kao
Journal:  J Vis Exp       Date:  2012-09-25       Impact factor: 1.355

Review 5.  Review: insights gained from modelling high-grade glioma in the mouse.

Authors:  S L Rankin; G Zhu; S J Baker
Journal:  Neuropathol Appl Neurobiol       Date:  2012-06       Impact factor: 8.090

6.  Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells.

Authors:  Yukti Choudhury; Felix Chang Tay; Dang Hoang Lam; Edwin Sandanaraj; Carol Tang; Beng-Ti Ang; Shu Wang
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

7.  Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.

Authors:  Neha Kamran; Marianela Candolfi; Gregory J Baker; Mariela Moreno Ayala; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Methods Mol Biol       Date:  2016

Review 8.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

9.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

10.  Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Authors:  C Albanese; R Alzani; N Amboldi; A Degrassi; C Festuccia; F Fiorentini; Gl Gravina; C Mercurio; W Pastori; Mg Brasca; E Pesenti; A Galvani; M Ciomei
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.